Study objectives and endpoints
ADVERSE EVENTS
This is a phase 1, partially blinded study with the primary objective to evaluate how DENV immune status (seronegative, non-DENV3 monotypic, or polytypic) modulates safety and protection against immunization with live-attenuated monovalent vaccine rDEN3Δ30/31-7164 (Fig. 
Trial design. Baseline immune status of each group and expected outcome after DENV3 vaccination (
Study Objectives and Endpoints (Selected)ADE, antibody dependent enhancement; AE, adverse events; AIM, activation induced marker assays; GMT, geometric mean titer; SAE, severe adverse events